PIRS Pieris Pharmaceuticals
- 11.3700
- +0.1500+1.34%
- 11.4800
- +0.1100+0.97%
Pieris Pharmaceuticals News
Pieris Pharmaceuticals | 10-Q: Quarterly report
Pieris Pharmaceuticals Received Nasdaq Notice Stating For Last 10 Consecutive Business Says, Closing Bid Price Was At $1 Or Greater
Pieris Pharmaceuticals Received Nasdaq Notice Stating For Last 10 Consecutive Business Says, Closing Bid Price Was At $1 Or Greater
Little Excitement Around Pieris Pharmaceuticals, Inc.'s (NASDAQ:PIRS) Revenues As Shares Take 27% Pounding
Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) shareholders won't be pleased to see that the share price has had a very rough month, dropping 27% and undoing the prior period's positive performance. Fo
Pieris Pharmaceuticals To Carry Out 1-for-80 Reverse Stock Split On April 23rd, 2024
April 20th - $Pieris Pharmaceuticals(PIRS.US)$ is about to implement a 1-for-80 reverse stock split of shares. The shares will begin trading on a split-adjusted basis from April 23rd, 2024.$Pieris Pha
Pieris Pharmaceuticals Announces 1-for-80 Reverse Stock Split
BOSTON, MA / ACCESSWIRE / April 19, 2024 / Pieris Pharmaceuticals, Inc. today announced that its Board of Directors has approved a 1-for-80 reverse stock split of the Company's common stock, par value
Pieris Pharmaceuticals Enacts Reverse Stock Split for NASDAQ Compliance
Pieris Pharmaceuticals Announces Strategy to Maximize Partnered Milestone and Royalty Potential
BOSTON, MA / ACCESSWIRE / March 27, 2024 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) provided a corporate update today announcing a strategy to maximize its ability to capture the potential milestone
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
GainersEtao International Co (NASDAQ:ETAO) shares increased by 180.5% to $0.4 during Wednesday's pre-market session. The company's market cap stands at $40.4 million. Jaguar Health (NASDAQ:JAGX) stock
12 Health Care Stocks Moving In Thursday's After-Market Session
GainersGeron (NASDAQ:GERN) stock increased by 90.8% to $3.34 during Thursday's after-market session. The market value of their outstanding shares is at $1.8 billion. Madrigal Pharmaceuticals (NASDAQ:M
Prime Medicine Names Foghorn Therapeutics' CFO to Be Its New Finance Chief
Prime Medicine (PRME) said Friday it has selected a new chief financial officer, with Allan Reine slated to join the biotechnology genetic therapies company on Jan. 17. Reine joins the company from hi
Investors Don't See Light At End Of Pieris Pharmaceuticals, Inc.'s (NASDAQ:PIRS) Tunnel And Push Stock Down 27%
Will Pieris Pharmaceuticals (NASDAQ:PIRS) Spend Its Cash Wisely?
Pieris Pharmaceuticals (PIRS) Upgraded to Strong Buy: Here's Why
12 Health Care Stocks Moving In Friday's Pre-Market Session
GainersYS Biopharma Co (NASDAQ:YS) shares moved upwards by 72.0% to $1.34 during Friday's pre-market session. The company's market cap stands at $124.6 million. Longeveron Inc. - Subscription Right (N
Is Pieris Pharmaceuticals (PIRS) a Value Trap? A Comprehensive Analysis
Pieris Pharmaceuticals (PIRS) Upgraded to Strong Buy: Here's What You Should Know
Pieris Pharmaceuticals Says Patient Dosing in Cancer Drug Trial Triggers Milestone Payment From Boston Pharmaceuticals
Pieris Pharmaceuticals (PIRS) said Thursday the dosing of the first patient in a phase 1/2 trial of cancer drug candidate BOS-342 triggered a milestone payment from Boston Pharmaceuticals. The study w
Pieris Pharmaceuticals Has Achieved An Undisclosed Milestone Payment From Boston Pharmaceuticals Based On Dosing The First Patient In A Boston Pharmaceutical-Sponsored Phase 1/2 Study Of BOS-342 (Formerly PRS-342)
Pieris Pharmaceuticals Has Achieved An Undisclosed Milestone Payment From Boston Pharmaceuticals Based On Dosing The First Patient In A Boston Pharmaceutical-Sponsored Phase 1/2 Study Of BOS-342 (Form
Pieris Pharmaceuticals Announces Milestone Achievement for Boston Pharmaceuticals' Initiation of Phase 1/2 Study of BOS-342, a 4-1BB/GPC3 Immuno-Oncology Bispecific
BOSTON, MA / ACCESSWIRE / August 17, 2023 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS), a clinical-stage biotechnology company focused on novel biotherapeutics through its proprietary Anticalin® technology platform for respiratory diseases and cancer, today announced that the Company has achieved an undisclosed milestone payment from Boston Pharmaceuticals.
12 Health Care Stocks Moving In Wednesday's After-Market Session
GainersModular Medical (NASDAQ:MODD) stock rose 33.3% to $1.36 during Wednesday's after-market session. Trading volume for this security closed at 1.4 million, accounting for 2289.8% of its average fu
Analysis
Price Target
No Data
